The burden of chronic hyperglycemia

被引:19
作者
Clark, CM [1 ]
机构
[1] Indiana Univ, Med Ctr, Regenstrief Inst Hlth Care, Regenstrief Hlth Ctr, Indianapolis, IN 46202 USA
关键词
D O I
10.2337/diacare.21.3.C32
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetic complications constitute the principal clinical and economic burdens of diabetes. Available evidence indicates that sustained reduction in hyperglycemia las measured by HbA(1c)) reduces the incidence of diabetic complications, including microvascular and neurological disease, and will likely reduce the risk of macrovascular disease. in the U.S., targeting interventions to aged and ethnic subpopulations, which are currently receiving suboptimal care, and increasing efforts to lower the average HbA(1c) concentrations one or two percentage points in people with diabetes would be a more cost-effective goal than aiming for a theoretical HbA(1c) threshold below which the risk of complications is negligible. Other risk factors for diabetic complications, such as obesity hypertension, cigarette smoking, and hypercholesterolemia, must. also be addressed to reduce the burden of diabetes.
引用
收藏
页码:C32 / C34
页数:3
相关论文
共 19 条
  • [1] Cardiovascular events and correlates in the Veterans Affairs diabetes feasibility trial - Veterans Affairs Cooperative Study on gylcemic control and complications in type II diabetes
    Abraira, C
    Colwell, J
    Nuttall, F
    Sawin, CT
    Henderson, W
    Comstock, JP
    Emanuele, NV
    Levin, SR
    Pacold, I
    Lee, HS
    Silbert, CK
    Cxypoliski, R
    Vasquez, M
    Kernan, D
    Niewoehner, C
    Backes, M
    Bradley, M
    Bradley, M
    Crow, R
    Rubino, F
    Bushnell, D
    Pfeifer, M
    Service, FJ
    Howard, B
    Chew, E
    Hoogwerf, B
    Seigel, D
    Clark, CM
    Olefsky, JM
    Porte, D
    Sussman, KE
    Johnson, N
    Christine, B
    Tir, K
    Sather, M
    Day, P
    Morgan, N
    Deykin, D
    Gold, J
    Huang, P
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (02) : 181 - 188
  • [2] *AM DIAB ASS, 1996, DIABETES CARE S1, V19, pS96
  • [3] [Anonymous], 1995, DIABETES, V44, P968
  • [4] Intensive insulin therapy in type II diabetes - Rationale and collaborative clinical trial results
    Colwell, JA
    [J]. DIABETES, 1996, 45 : S87 - S90
  • [5] THE TRIUMVIRATE - BETA-CELL, MUSCLE, LIVER - A COLLUSION RESPONSIBLE FOR NIDDM
    DEFRONZO, RA
    [J]. DIABETES, 1988, 37 (06) : 667 - 687
  • [6] EFFECT OF DIFFERENCES IN GLUCOSE-TOLERANCE ON INSULINS ABILITY TO REGULATE CARBOHYDRATE AND FREE FATTY-ACID METABOLISM IN OBESE INDIVIDUALS
    GOLAY, A
    CHEN, YDI
    REAVEN, GM
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1986, 62 (06) : 1081 - 1088
  • [7] Risk factors for myocardial infarction and death in newly detected NIDDM: The diabetes intervention study, 11-year follow-up
    Hanefeld, M
    Fischer, S
    Julius, U
    Schulze, J
    Schwanebeck, U
    Schmechel, H
    Ziegelasch, HJ
    Lindner, J
    [J]. DIABETOLOGIA, 1996, 39 (12) : 1577 - 1583
  • [8] EPIDEMIOLOGIC CORRELATES OF NIDDM IN HISPANICS, WHITES, AND BLACKS IN THE UNITED-STATES POPULATION
    HARRIS, MI
    [J]. DIABETES CARE, 1991, 14 (07) : 639 - 648
  • [9] VARIATIONS IN INSULIN-STIMULATED GLUCOSE-UPTAKE IN HEALTHY-INDIVIDUALS WITH NORMAL GLUCOSE-TOLERANCE
    HOLLENBECK, C
    REAVEN, GM
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1987, 64 (06) : 1169 - 1173
  • [10] GLYCOSYLATED HEMOGLOBIN PREDICTS THE INCIDENCE AND PROGRESSION OF DIABETIC-RETINOPATHY
    KLEIN, R
    KLEIN, BEK
    MOSS, SE
    DAVIS, MD
    DEMETS, DL
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1988, 260 (19): : 2864 - 2871